Orion gives up on early use of Stalevo in Parkinson's in the EU
This article was originally published in Scrip
Executive Summary
Orion has decided to withdraw its EU application for extending the indication for Orion and Novartis's Parkinson's disease treatment, Stalevo (a combination formulation of carbidopa, levodopa and entacapone), following last month's failure of the STRIDE-PD trial, investigating it as a first-line treatment.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.